Aimmune Therapeutics (AIMT) Reports In-Line Q3 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Aimmune Therapeutics (AIMT) Reports In-Line Q3 EPS

Aimmune Therapeutics (AIMT) Reports AR101 Demonstrates Consistent Efficacy & Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data

November 8, 2019 7:16 AM EST

Aimmune Therapeutics, Inc. (NASDAQ: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the results from a new analysis showing consistent efficacy and safety with AR101 across the phase 3 PALISADE and ARTEMIS trials, despite differing regions of study, entry criteria, therapeutic dosing periods and primary efficacy endpoints. The data were presented at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting in Houston.

The study comparison found substantially and significantly higher proportions of AR101-treated patients were able to tolerate clinically meaningful quantities of peanut... More